Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution

BMC Gastroenterology

Volumn 15, Issue 1, 2015, Pages

  Nozaki, Yuichi ^a,b   Fujita, Koji ^a   Wada, Koichiro ^c   Yoneda, Masato ^a   Shinohara, Yoshiyasu ^a   Imajo, Kento ^a   Ogawa, Yuji ^a   Kessoku, Takaomi ^a   Nakamuta, Makoto ^d   Saito, Satoru ^a   Masaki, Naohiko ^e   Nagashima, Yoji ^a,f   Terauchi, Yasuo ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^e 1 7 1 Kohnodai   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Fat distribution; Hepatic tissue blood flow; NAFLD; NO; Obese mice

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NITRIC OXIDE; CARRIER PROTEIN; NOS3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOWN REGULATION; ENZYME DEFICIENCY; HEPATITIS; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KNOCKOUT MOUSE; LIPID DIET; LIPID STORAGE; LIVER BLOOD FLOW; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; WILD TYPE; ADVERSE EFFECTS; ANIMAL; DEFICIENCY; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; PATHOLOGY; VASCULARIZATION;

ANIMALS; CARRIER PROTEINS; DIET, HIGH-FAT; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84949948412     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-015-0409-9     Document Type: Article

References (38)

1. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-5.
2. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009;50:772-80.
3. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, et al. Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling. Cell Metab. 2012;3(16):44-54.
4. Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol. 2009;51:548-56.
5. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthase: structure, function and inhibition. Biochem J. 2001;357:593-615.
6. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009;20:295-302.
7. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004;40:386-93.
8. Sheldon RD, Padilla J, Jenkins NT, Laughlin MH, Rector RS. Chronic NOS inhibition accelerates NAFLD progression in an obese rat model. Am J Physiol Gastrointest Liver Physiol. 2015;15(308):G540-9.
9. Toshima G, Iwama Y, Kimura F, Matsumoto Y, Miura M, Takahashi J, et al. LipoSERCH®; Analytical GP-HPLC method for lipoprotein profiling and its applications. J Biol Macromol. 2013;13:21-32.
10. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002;43:805-14.
11. Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest. 2007;117:246-57.
12. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003;38:133-40.
13. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16:185-94.
14. Theeraladanon C, Takahashi N, Shiina M, Hamada K, Takada Y, Endo H, et al. Rational approach to the synthesis, evaluation, and (68)ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase. Cancer Biother Radiopharm. 2010;25:479-85.
15. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105-12.
16. Judex S, Luu YK, Ozcivici E, Adler B, Lublinsky S, Rubin CT. Quantification of adiposity in small rodents using micro-CT. Methods. 2010;50:14-9.
17. Eguchi Y, Mizuta T, Sumida Y, Ishibashi E, Kitajima Y, Isoda H, et al. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol. 2011;46 Suppl 1:70-8.
18. Luu YK, Lublinsky S, Ozcivici E, Capilla E, Pessin JE, Rubin CT, et al. In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model. Med Eng Phys. 2009;31:34-41.
19. Ishikawa H, Jin MB, Ogata T, Taniguchi M, Suzuki T, Shimamura T, et al. Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers. Transplantation. 2002;73:1041-8.
20. Masuko H, Jin MB, Horiuchi H, Suzuki T, Taniguchi M, Shimamura T, et al. Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. Transplantation. 2001;71:1034-9.
21. Khandoga A, Huettinger S, Khandoga AG, Li H, Butz S, Jauch KW, et al. Leukocyte transmigration in inflamed liver: A role for endothelial cell-selective adhesion molecule. J Hepatol. 2009;50:755-65.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.
23. Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57:1583-91.
24. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836-46.
25. Seifalian AM, El-Desoky A, Davidson BR. Hepatic indocyanine green uptake and excretion in a rabbit model of steatosis. Eur Surg Res. 2001;33:193-201.
26. Shigefuku R, Takahashi H, Kobayashi M, Ikeda H, Matsunaga K, Okuse C, et al. Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? J Gastroenterol. 2012;47:1238-47.
27. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894-8.
28. Le Gouill E, Jimenez M, Binnert C, Jayet PY, Thalmann S, Nicod P, et al. Endothelial nitric oxide synthase (eNOS) knockout mice have defective mitochondrial beta-oxidation. Diabetes. 2007;56:2690-6.
29. Nisoli E, Clementi E, Carruba MO, Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res. 2007;100:795-806.
30. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, et al. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly. 2003;133:360-3.
31. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342-5.
32. Durand JL, Nawrocki AR, Scherer PE, Jelicks LA. Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase. J Cell Biochem. 2012;113:3276-87.
33. Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest. 2008;88:515-28.
34. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003;299:896-9.
35. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol. 2004;40:781-6.
36. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken). 2008;291:684-92.
37. Oda M, Yokomori H, Han JY. Regulatory mechanisms of hepatic microcirculation. Clin Hemorheol Microcirc. 2003;29:167-82. Review.
38. Rosenstengel S, Stoeppeler S, Bahde R, Spiegel HU, Palmes D. Type of steatosis influences microcirculation and fibrogenesis in different rat strains. J Invest Surg. 2011;24:273-82.